Otar Chokoshvili

Otar Chokoshvili

Auto-generated profile, based on publicly available information

Otar Chokoshvili

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SASanaa A. Ahmed
Sanaa A. Ahmed
JAJoy Awosika
Joy Awosika
CBCarson Baldwin
Carson Baldwin
KBKimberly Bishop-Lilly
Kimberly Bishop-Lilly
BBBiswajit Biswas
Biswajit Biswas
TCThreat Characterization Consortium
Threat Characterization Consortium
In May of 2011, an enteroaggregative Escherichia coli O104:H4 strain that had acquired a Shiga toxin 2-converting phage caused a large outbreak of bloody diarrhea in Europe which was notable for its high prevalence of hemolytic uremic syndrome cases. Several studies have described the genomic inventory and phylogenies of strains associated with the outbreak and a collection of historical E. coli O104:H4 isolates using draft genome assemblies. We present the complete, closed genome sequences of an isolate from the 2011 outbreak (2011C–3493) and two isolates from cases of bloody diarrhea that occurred in the Republic of Georgia in 2009 (2009EL–2050 and 2009EL–2071). Comparative genome analysis indicates that, while the Georgian strains are the nearest neighbors to the 2011 outbreak isolates sequenced to date, structural and nucleotide-level differences are evident in the Stx2 phage genomes, the mer/tet antibiotic resistance island, and in the prophage and plasmid profiles of the strains, including a previously undescribed plasmid with homology to the pMT virulence plasmid of Yersinia pestis. In addition, multiphenotype analysis showed that 2009EL–2071 possessed higher resistance to polymyxin and membrane-disrupting agents. Finally, we show evidence by electron microscopy of the presence of a common phage morphotype among the European and Georgian strains and a second phage morphotype among the Georgian strains. The presence of at least two stx2 phage genotypes in host genetic backgrounds that may derive from a recent common ancestor of the 2011 outbreak isolates indicates that the emergence of stx2 phage-containing E. coli O104:H4 strains probably occurred more than once, or that the current outbreak isolates may be the result of a recent transfer of a new stx2 phage element into a pre-existing stx2-positive genetic background.

12 June 2014 in HIV Medicine
Verified
Journal Article
Open access
PDF file
NCN Chkhartishvili
N Chkhartishvili
LSL Sharavdze
L Sharavdze
OCO Chokoshvili
O Chokoshvili
JDJA DeHovitz
JA DeHovitz
CRC del Rio
C del Rio
TTT Tsertsvadze
T Tsertsvadze
Objectives: Individual and public health benefits of antiretroviral therapy (ART) rely on successful engagement of HIV‐infected patients in care. We aimed to evaluate the HIV care continuum in the Eastern European country of Georgia.Methods: The analysis included all adult (age ≥ 18 years) HIV‐infected patients diagnosed in Georgia from January 1989 until June 2012. Data were extracted from the national HIV/AIDS database as of 1 October 2012. The following stages of the HIV care continuum were quantified: HIV infected, HIV diagnosed, linked to care, retained in care, eligible for ART and virologically suppressed.Results: Of 3295 cumulative cases of adult HIV infection reported in Georgia, 2545 HIV‐infected patients were known to be alive as of 1 October 2012, which is 52% of the estimated 4900 persons living with HIV in the country. Of the 2545 persons diagnosed with HIV infection, 2135 (84%) were linked to care and 1847 (73%) were retained in care. Of 1446 patients eligible for ART, 1273 (88%) were on treatment and 985 (77%) of them had a viral load < 400 HIV‐1 RNA copies/mL. Overall, 39% of those diagnosed and 20% of those infected had a suppressed viral load.Conclusions: The findings of our analysis demonstrate that the majority of patients diagnosed with HIV infection are retained in care. Loss of patients occurs at each step of the HIV care continuum, but the major gap is at the stage of HIV diagnosis. Reducing the number of persons living with undiagnosed HIV infection and simultaneously enhancing engagement in continuous care will be critical to achieve maximum individual and public health benefits of ART.

1 June 2014 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
LSLali Sharvadze
Lali Sharvadze
OCOtar Chokoshvili
Otar Chokoshvili
NBNatalia Bolokadze
Natalia Bolokadze
NRNino Rukhadze
Nino Rukhadze
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
Since 2004, the country of Georgia has provided antiretroviral therapy (ART) to all patients in need. A nationwide retrospective cohort study was conducted to assess the effect of universal access to ART on patterns of mortality and causes of death among HIV-infected individuals in Georgia. All known HIV-infected adult individuals (age ≥18 years) diagnosed from 1989 through 2012 were included. Rates and causes of death were determined using routinely collected data from the national HIV/AIDS database. Causes of death were classified according to the Coding of Death in HIV (CoDe) protocol. Between 1989 and 2012, 3,554 HIV-infected adults were registered in Georgia contributing to 13,572 person-years (PY) of follow-up. A total of 779 deaths were registered during follow-up. The mortality rate peaked in 2004 with 10.74 deaths per 100 PY (95% CI: 7.92-14.24) and significantly decreased after the universal availability of ART to 4.02 per 100 PY (95% CI: 3.28-4.87) in 2012. In multivariate analysis the strongest predictor of mortality was having AIDS at the time of HIV diagnosis (hazard ratio: 5.69, 95% CI: 4.72-6.85). AIDS-related diseases accounted for the majority of deaths (n=426, 54.7%). Tuberculosis (TB) was the leading cause of death accounting for 21% of the total deaths reported. Universal access to ART significantly reduced mortality among HIV-infected patients in Georgia. However, overall mortality rates remain high primarily due to late diagnosis, and TB remains a significant cause of death. Improving rates of early HIV diagnosis and ART initiation may further decrease mortality as well as prevent new HIV and TB infections.

30 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
OCOtar Chokoshvili
Otar Chokoshvili
NBNatalia Bolokadze
Natalia Bolokadze
MTMaya Tsintsadze
Maya Tsintsadze
LSLali Sharvadze
Lali Sharvadze
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
Late presentation for HIV care has important individual and population implications. The objective of this study was to explore the problem of late presentation in the country of Georgia. Data on adult persons newly diagnosed with HIV in Georgia between 2012 and 2015 were extracted from the national AIDS Health Information System. Late presenter was defined as a person diagnosed with HIV with a CD4 cell count <350 cells/mm3 or an AIDS defining illness regardless of the CD4 cell count in the six months after HIV diagnosis. Late presenter with advanced disease was defined as a person diagnosed with HIV with a CD4 cell count <200 cells/mm3 or an AIDS defining illness, regardless of CD4 cell count in the six months after HIV diagnosis. Among 2267 adults diagnosed with HIV in Georgia in 2012–2015, 1987 (87.6%) had CD4 cell count measured within 6 months of HIV diagnosis and were included in the analysis. Among them 1260 (63.4%) patients were classified as late presenters and 870 (43.8%) as late presenters with advanced disease. The proportion of late presenters declined from 71.1% in 2012 to 55.5% in 2015 (p<0.0001), while presentation late with advanced disease decreased from 56.6% in 2012 to 34.5% in 2015 (p<0.0001). Late presentation was most common among people who inject drugs (77.7%). Overall 186 patients died over the studied period. Mortality was higher both among late presenters (6.74 per 100 person-years vs. 1.08 per 100 person-years, p<0.0001) and late presenters with advanced disease (8.93 per 100 person-years vs. 1.34 per 100 person-years, p<0.0001). High prevalence of late presentation in Georgia reflects insufficiency in HIV testing services. Better testing strategies are needed to improve earlier diagnosis and disease outcomes.

1 January 2014 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
NCNikoloz Chkhartishvili
Nikoloz Chkhartishvili
LSLali Sharvadze
Lali Sharvadze
NDNatia Dvali
Natia Dvali
MKMarine Karchava
Marine Karchava
NRNino Rukhadze
Nino Rukhadze
TTTengiz Tsertsvadze
Tengiz Tsertsvadze
Data on the effectiveness of second-line antiretroviral therapy (ART) in resource-limited countries of Eastern Europe is limited. Objective of this study was to evaluate virological outcomes of second-line ART in Georgia.

10 May 2019 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AHAaron M. Harris
Aaron M. Harris
OCOtar Chokoshvili
Otar Chokoshvili
JBJoshua Biddle
Joshua Biddle
KTKostantine Turashvili
Kostantine Turashvili
MJMaia Japaridze
Maia Japaridze
FAFrancisco Averhoff
Francisco Averhoff
The country of Georgia has a high burden of chronic hepatitis C virus (HCV) infection, and prisoners are disproportionately affected. During 2013, a novel program offering no cost screening and treatment of HCV infection for eligible prisoners was launched. The HCV treatment program implemented a voluntary opt-in anti-HCV testing policy to all prisoners. Anti-HCV positive persons received HCV RNA and genotype testing. Transient elastography was also performed on prisoners with positive HCV RNA results. Prisoners with chronic HCV infection who had ≥F2 Metavir stage for liver fibrosis and a prison sentence ≥ 6 months were eligible for interferon-based treatment, which was the standard treatment prior to 2015. We conducted an evaluation of the HCV treatment program among prisoners from the program’s inception in December 2013 through April 2015 by combining data from personal interviews with corrections staff, prisoner data in the corrections database, and HCV-specific laboratory information. Of an estimated 30,000 prisoners who were incarcerated at some time during the evaluation period, an estimated 13,500 (45%) received anti-HCV screening, of whom 5175 (38%) tested positive. Of these, 3840 (74%) received HCV RNA testing, 2730 (71%) tested positive, and 880 (32%) met treatment eligibility. Of these, 585 (66%) enrolled; 405 (69%) completed treatment, and 202 (50%) achieved a sustained virologic response at least 12 weeks after treatment completion. HCV infection prevalence among Georgian prisoners was high. Despite challenges, we determined HCV treatment within Georgian Ministry of Correction facilities was feasible. Efforts to address HCV infection among prison population is one important component of HCV elimination in Georgia.